Four months of Ivacaftor therapy improved β-cell function, enhancing insulin secretion and glucagon control, but did not significantly alter glucose tolerance or incretin secretion. These findings suggest that Ivacaftor may help prevent CFRD, but long-term studies are needed to confirm these effects. The gene discussed is GCG; the disease is cystic fibrosis-related diabetes.